(Q36017772)

11 August 2017

1 reference

title

Apoptosis-based therapies and drug targets (English)

1 reference

11 August 2017

1 reference

Fischer U

1

1 reference

11 August 2017

Schulze-Osthoff K

series ordinal

2

1 reference

11 August 2017

publication date

1 August 2005

1 reference

Cell Death & Differentiation

11 August 2017

published in

1 reference

11 August 2017

volume

12 Suppl 1

1 reference

11 August 2017

page(s)

942-961

1 reference

Apoptosis signaling by death receptors.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The kiss of death: promises and failures of death receptors and ligands in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Potential and caveats of TRAIL in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

TNF-alpha antagonists for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Multiple sclerosis: Fas signaling in oligodendrocyte cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Many cuts to ruin: a comprehensive update of caspase substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The protein structures that shape caspase activity, specificity, activation and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Prevention of lymphocyte cell death in sepsis improves survival in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Non-specific effects of methyl ketone peptide inhibitors of caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Peptide based interleukin-1 beta converting enzyme (ICE) inhibitors: synthesis, structure activity relationships and crystallographic study of the ICE-inhibitor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A novel nonpeptidic caspase-3/7 inhibitor, (S)-(+)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin reduces myocardial ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Nicotinyl aspartyl ketones as inhibitors of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

In situ assembly of enzyme inhibitors using extended tethering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The design and synthesis of sulfonamides as caspase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Characterization of IDN-6556 (3-[2-(2-tert-butyl-phenylaminooxalyl)-amino]-propionylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid): a liver-targeted caspase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Synthetic activation of caspases: artificial death switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Maintenance of caspase-3 proenzyme dormancy by an intrinsic "safety catch" regulatory tripeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

RGD peptides induce apoptosis by direct caspase-3 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Direct activation of the apoptosis machinery as a mechanism to target cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

IAP proteins: blocking the road to death's door

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

IAP family proteins--suppressors of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

BIRinging chromosomes through cell division--and survivin' the experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Structural basis for the inhibition of caspase-3 by XIAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

NMR structure and mutagenesis of the third Bir domain of the inhibitor of apoptosis protein XIAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Peptides targeting caspase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Structural basis of IAP recognition by Smac/DIABLO

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The inhibitor of apoptosis protein-binding domain of Smac is not essential for its proapoptotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The Bcl-2 family: roles in cell survival and oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand, antimycin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

BH3-domain mimetic compound BH3I-2' induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Identification of chelerythrine as an inhibitor of BclXL function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Intracellular antibody-caspase-mediated cell killing: an approach for application in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Ablation of microvessels in vivo upon dimerization of iCaspase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Cancer gene therapy using a survivin mutant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Caspase inhibitors reduce neuronal injury after focal but not global cerebral ischemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Increased Fas antigen on T cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Disulfiram is a potent inhibitor of proteases of the caspase family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Identification of potent and novel small-molecule inhibitors of caspase-3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Conformationally constrained inhibitors of caspase-1 (interleukin-1 beta converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Stressful death of T-ALL tumor cells after treatment with the anti-tumor agent Tetrocarcin-A.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Pharmacological rescue of mutant p53 conformation and function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CDD.4401556

7 January 2021

Identifiers

DOI

10.1038/SJ.CDD.4401556

1 reference

11 August 2017

1 reference